N/A N=8 Body Signal Integration Training: A Case Series
Functional Neurological Disorder
Primary: Number of Participants That Complete 80% of the Intervention — 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=65 Intraosseous Morphine in Primary TKA
Knee Disease · Arthritis Knee · Pain, Acute
Primary: Post-operative Pain — 4.29; 3.57 visual analog pain scale
Phase 2 N=24 Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
Invasive Breast Carcinoma · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7
Primary: RCB Status — 4; 6; 8; 6 Participants
Phase 3 N=7,529 A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
Herpes Zoster · Herpes Zoster Vaccine
Primary: Number of Participants Having at Least One Confirmed Herpes Zoster (HZ) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall — 69; 341 Participants
Phase 2 N=51 Dual-task Augmented Reality Treatment for Parkinson's Disease
Parkinson Disease
Primary: Gait Velocity — 1.20; 1.22; 1.03; 1.07 meters/second
Phase 2 N=71 A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
Antipsychotic-induced Weight Gain (AIWG)
Primary: Change From Baseline in Body Weight at Week 12 for 600 mg Miricorilant Versus Placebo — -0.98; -1.08 kg — p=0.8511
N/A N=80 Primary-Care Based Mindfulness Intervention
Post Traumatic Stress Disorder · Major Depressive Disorder
Primary: Number of Participants Retained in Study — 22; 26 Participants
Phase 3 N=110 Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period
Narcolepsy With Cataplexy · Narcolepsy Without Cataplexy
Primary: To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. — -6.29; -2.60 score on a scale
N/A N=23 Spinal Plasticity to Enhance Motor Retraining After Stroke
Stroke · Cerebrovascular Accident · Hemiparesis
Primary: Motor Control & Learning — 0.339; 0.359; 0.301 Newton
N/A N=230 Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)
COVID-19 · Coronavirus Infection · SARS CoV 2 Infection
Primary: Change in Quantitative Polymerase Chain Reaction (qPCR) From Baseline to 30 Minutes — 0.0345; -0.5577; -1.4789; 0.2339 natural log copies/20μL sample — p=0.59
Phase 1 N=61 Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study
Blood Loss, Surgical
Primary: Blood Loss — 122.6; 133.3 cubic centimeters
N/A N=100 iSTEP - an mHealth Physical Activity and Diet Intervention for Persons With HIV
HIV/AIDS
Primary: Physical Activity - Total Steps Recorded During 24 Weeks — 1345700; 1686395; 1684843 steps
N/A N=312 A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: Age of Participants When They Failed to Walk — NA; 14.4; 14.4; 11.1 Years
N/A N=26 Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors
Cancer Survivors · African Americans · Women
Primary: Participants Who Met Inclusion Criteria Compared to Participants Approached — 13; 13 Participants
Phase 2 N=38 A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Elranatamab · Myeloma · Multiple Myeloma
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) — 1 Participants